Invention Grant
- Patent Title: Heterocyclic compounds for inhibiting TYK2 activities
-
Application No.: US17736866Application Date: 2022-05-04
-
Publication No.: US11578058B2Publication Date: 2023-02-14
- Inventor: Xiangyang Chen , Yucheng Pang
- Applicant: Beijing InnoCare Pharma Tech Co., Ltd.
- Applicant Address: CN Beijing
- Assignee: Beijing InnoCare Pharma Tech Co., Ltd.
- Current Assignee: Beijing InnoCare Pharma Tech Co., Ltd.
- Current Assignee Address: CN Beijing
- Agency: Perkins Coie LLP
- Agent Viola Kung
- Main IPC: C07D403/12
- IPC: C07D403/12
Abstract:
The present invention is directed to Compounds 1-8, and their pharmaceutically acceptable salts or prodrugs thereof. Compounds 1-8 are selective binders to TYK2's JH2 and they exhibit significant inhibitory effects on the physiological function of TYK2 and they have excellent in vivo pharmacokinetic properties. Compounds 1-5 and 7 have several deuterium substitutions on methyl to improve pharmacokinetic (PK) properties.
Public/Granted literature
- US20220259184A1 HETEROCYCLIC COMPOUNDS FOR INHIBITING TYK2 ACTIVITIES Public/Granted day:2022-08-18
Information query
